ILUMYA plus halobetasol ointment for plaque psoriasis
Part of Skin clinical trials.
This trial studies whether ILUMYA (an injection) working together with halobetasol ointment helps control moderate-to-severe plaque psoriasis. It is meant for adults whose psoriasis is significant enough that they may need light therapy (phototherapy) and/or pills/injections (systemic therapy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have plaque psoriasis that is moderate-to-severe (based on your doctor’s scoring such as PASI and BSA).
- Your care team says you are a candidate for phototherapy and/or systemic (whole-body) treatment.
- If you can become pregnant: you must have negative pregnancy tests at screening and before starting baseline treatment, and use approved birth control during the study.
- You must not have active or untreated latent tuberculosis (TB).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether narrowband ultraviolet B (UVB) light given three times a week for 12 weeks improves moderate-to-severe plaque psoriasis. It is an “open-label” pilot, meaning everyone gets the UVB treatment and researchers track how your skin responds.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial tests a new medication called HSK44459 for people with moderate to severe plaque psoriasis who need systemic therapy (medicine that works throughout the body). The goal is to see if it is safe and effective.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.